Lack of association between response of OROS-methylphenidate and norepinephrine transporter (SLC6A2) polymorphism in Korean ADHD

Psychiatry Research

Volumn 186, Issue 2-3, 2011, Pages 338-344

  Lee, Sung Hee ^a   Kim, So Won ^a   Lee, Min Goo ^a   Yook, Ki Hwan ^b   Greenhill, Laurence L ^c   Frandin, Kelly N ^c   Hong, Hyun Ju ^d  

^a Yonsei University College of Medicine   (South Korea)

^b CHA University   (South Korea)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d Hallym University   (South Korea)

Author keywords

ADHD; Methylphenidate; Norepinephrine transporter; Pharmacogenetics; Polymorphism

Indexed keywords

METHYLPHENIDATE;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION DEFICIT HYPERACTIVITY DISORDER RATING SCALE; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG RESPONSE; FEMALE; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; NOREPINEPHRINE TRANSPORTER GENE; NUCLEOTIDE SEQUENCE; OPEN STUDY; PHARMACOGENETICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; FEMALE; GENE FREQUENCY; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; KOREA; LINKAGE DISEQUILIBRIUM; MALE; METHYLPHENIDATE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79952360908     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2010.08.033     Document Type: Article

References (54)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) 1994, American Psychiatric Association, Washington, DC.
2. Andrews G.D., Lavin A. Methylphenidate increases cortical excitability via activation of alpha-2 noradrenergic receptors. Neuropsychopharmacology 2006, 31:594-601.
3. Arnsten A.F., Li B.M. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biological Psychiatry 2005, 57:1377-1384.
4. Arnsten A.F., Steere J.C., Hunt R.D. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Archives of General Psychiatry 1996, 53:448-455.
5. Barr C.L., Kroft J., Feng Y., Wigg K., Roberts W., Malone M., Ickowicz A., Schachar R., Tannock R., Kennedy J.L. The norepinephrine transporter gene and attention-deficit hyperactivity disorder. American Journal of Medical Genetics 2002, 114:255-259.
6. Berridge C.W., Devilbiss D.M., Andrzejewski M.E., Arnsten A.F., Kelley A.E., Schmeichel B., Hamilton C., Spencer R.C. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biological Psychiatry 2006, 60:1111-1120.
7. Biederman J., Kim J.W., Doyle A.E., Mick E., Fagerness J., Smoller J.W., Faraone S.V. Sexually dimorphic effects of four genes (COMT, SLC6A2, MAOA, SLC6A4) in genetic associations of ADHD: a preliminary study. Biological Psychiatry B Neuropsychiatric Genetics 2008, 147B:1511-1518.
8. Bobb A.J., Addington A.M., Sidransky E., Gornick M.C., Lerch J.P., Greenstein D.K., Clasen L.S., Sharp W.S., Inoff-Germain G., Wavrant-De Vrieze F., Arcos-Burgos M., Straub R.E., Hardy J.A., Castellanos F.X., Rapoport J.L. Support for association between ADHD and two candidate genes: NET1 and DRD1. American Journal of Medical Genetics B Neuropsychiatric Genetics 2005, 134B:67-72.
9. Brookes K., Xu X., Chen W., Zhou K., Neale B., Lowe N., Anney R., Franke B., Gill M., Ebstein R., Buitelaar J., Sham P., Campbell D., Knight J., Andreou P., Altink M., Arnold R., Boer F., Buschgens C., Butler L., Christiansen H., Feldman L., Fleischman K., Fliers E., Howe-Forbes R., Goldfarb A., Heise A., Gabriels I., Korn-Lubetzki I., Johansson L., Marco R., Medad S., Minderaa R., Mulas F., Muller U., Mulligan A., Rabin K., Rommelse N., Sethna V., Sorohan J., Uebel H., Psychogiou L., Weeks A., Barrett R., Craig I., Banaschewski T., Sonuga-Barke E., Eisenberg J., Kuntsi J., Manor I., McGuffin P., Miranda A., Oades R.D., Plomin R., Roeyers H., Rothenberger A., Sergeant J., Steinhausen H.C., Taylor E., Thompson M., Faraone S.V., Asherson P. The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Molecular Psychiatry 2006, 11:934-953.
10. Bruss M., Kunz J., Lingen B., Bonisch H. Chromosomal mapping of the human gene for the tricyclic antidepressant-sensitive noradrenaline transporter. Human Genetics 1993, 91:278-280.
11. Carter C.S., Braver T.S., Barch D.M., Botvinick M.M., Noll D., Cohen J.D. Anterior cingulate cortex, error detection, and the online monitoring of performance. Science 1998, 280:747-749.
12. Cho S.C., Kim J.W., Kim B.N., Hwang J.W., Park M., Kim S.A., Cho D.Y., Yoo H.J., Chung U.S., Son J.W., Park T.W. No evidence of an association between norepinephrine transporter gene polymorphisms and attention deficit hyperactivity disorder: a family-based and case-control association study in a Korean sample. Neuropsychobiology 2008, 57:131-138.
13. De Luca V., Muglia P., Jain U., Kennedy J.L. No evidence of linkage or association between the norepinephrine transporter (NET) gene MnlI polymorphism and adult ADHD. American Journal of Medical Genetics B Neuropsychiatric Genetics 2004, 124:38-40.
14. Faraone S.V., Perlis R.H., Doyle A.E., Smoller J.W., Goralnick J.J., Holmgren M.A., Sklar P. Molecular genetics of attention-deficit/hyperactivity disorder. Biological Psychiatry 2005, 57:1313-1323.
15. Faul F., Erdfelder E., Lang A.G., Buchner A. G*Power 3: a flexible statistical power analysis for the social, behavioral, and biomedical sciences. Behavior Research Methods 2007, 39:175-191.
16. Gau S.S., Shen H.Y., Soong W.T., Gau C.S. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan. Journal of Child and Adolescent Psychopharmacology 2006, 16:441-455.
17. Greenhill L.L., Pliszka S., Dulcan M.K., Bernet W., Arnold V., Beitchman J., Benson R.S., Bukstein O., Kinlan J., McClellan J., Rue D., Shaw J.A., Stock S. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child and Adolescent Psychiatry 2002, 41:26S-49S.
18. Grillner S., Hellgren J., Menard A., Saitoh K., Wikstrom M.A. Mechanisms for selection of basic motor programs-roles for the striatum and pallidum. Trends in Neurosciences 2005, 28:364-370.
19. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised 1976, US Department of Health Education and Welfare, Rockville, MD.
20. Han D.D., Gu H.H. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacology 2006, 6:6.
21. IMS health Inc. Market Measurement Data 2008.
22. Inoue K., Itoh K., Yoshida K., Shimizu T., Suzuki T. Positive association between T-182C polymorphism in the norepinephrine transporter gene and susceptibility to major depressive disorder in a Japanese population. Neuropsychobiology 2004, 50:301-304.
23. Joung Y., Kim C.H., Moon J., Jang W.S., Yang J., Shin D., Lee S., Kim K.S. Association studies of -3081(A/T) polymorphism of norepinephrine transporter gene with attention deficit/hyperactivity disorder in Korean population. American Journal of Medical Genetics B Neuropsychiatric Genetics 2009, 153B:691-694.
24. Kim B., Park E. An observational multi-center study for evaluation of efficacy, safety and parental satisfaction of methylphenidate-OROS in children with ADHD. Korean Journal of Child and Adolescent Psychiatry 2005, 22:498-512.
25. Kim Y.S., So Y.K., Choi N.K., Kim S.J., Koh Y.J. Normative data on the Korean ADHD Rating Scales (K-ARS) for parents and teachers. Journal of Korean Neuropsychiatric Association 2003, 42:352-359.
26. Kim Y.S., Cheon K.A., Kim B.N., Chang S.A., Yoo H.J., Kim J.W., Cho S.C., Seo D.H., Bae M.O., So Y.K., Noh J.S., Koh Y.J., McBurnett K., Leventhal B. The reliability and validity of Kiddie-Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version-Korean version (K-SADS-PL-K). Yonsei Medical Journal 2004, 45:81-89.
27. Kim C.H., Hahn M.K., Joung Y., Anderson S.L., Steele A.H., Mazei-Robinson M.S., Gizer I., Teicher M.H., Cohen B.M., Robertson D., Waldman I.D., Blakely R.D., Kim K.S. A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proceeding of the National Academy of Sciences of the United States of America 2006, 103:19164-19169.
28. Kim J.W., Biederman J., McGrath C.L., Doyle A.E., Mick E., Fagerness J., Purcell S., Smoller J.W., Sklar P., Faraone S.V. Further evidence of association between two NET single-nucleotide polymorphisms with ADHD. Molecular Psychiatry 2008, 13:624-630.
29. Kooij J.S., Boonstra A.M., Vermeulen S.H., Heister A.G., Burger H., Buitelaar J.K., Franke B. Response to methylphenidate in adults with ADHD is associated with a polymorphism in SLC6A3 (DAT1). American Journal of Medical Genetics B Neuropsychiatric Genetics 2008, 147:201-208.
30. Lee S.I., Hong S.D., Kim S.Y., Kim E.J., Kim J.H., Kim J.H., Park M.K., Park S., Park J.H., Oh E.Y., Lim T.S., Cheong S., Cho I.H., Choi J.W. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder. Progress in Neuropsychopharmacology and Biological Psychiatry 2007, 31:210-216.
31. Mick E., Neale B., Middleton F.A., McGough J.J., Faraone S.V. Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. American Journal of Medical Genetics B Neuropsychiatric Genetics 2008, 8:1412-1418.
32. Monchi O., Petrides M., Strafella A.P., Worsley K.J., Doyon J. Functional role of the basal ganglia in the planning and execution of actions. Annals of Neurology 2006, 59:257-264.
33. Moron J.A., Brockington A., Wise R.A., Rocha B.A., Hope B.T. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. Journal of Neuroscience 2002, 22:389-395.
34. MTA cooperative group A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal treatment study of children with ADHD. Archives of General Psychiatry 1999, 56:1073-1086.
35. Pacholczyk T., Blakely R.D., Amara S.G. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 1991, 350:350-354.
36. Pelham W.E., Gnagy E.M., Burrows-Maclean L., Williams A., Fabiano G.A., Morrisey S.M., Chronis A.M., Forehand G.L., Nguyen C.A., Hoffman M.T., Lock T.M., Fielbelkorn K., Coles E.K., Panahon C.J., Steiner R.L., Meichenbaum D.L., Onyango A.N., Morse G.D. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001, 107:E105.
37. Pliszka S.R., McCracken J.T., Maas J.W. Catecholamines in attention-deficit hyperactivity disorder: current perspectives. Journal of the American Academy of Child and Adolescent Psychiatry 1996, 35:264-272.
38. Polanczyk G., Zeni C., Genro J.P., Guimaraes A.P., Roman T., Hutz M.H., Rohde L.A. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Archives of General Psychiatry 2007, 64:218-224.
39. Porzgen P., Bonisch H., Bruss M. Molecular cloning and organization of the coding region of the human norepinephrine transporter gene. Biochemical and Biophysical Research Communications 1995, 215:1145-1150.
40. Ramoz N., Boni C., Downing A.M., Close S.L., Peters S.L., Prokop A.M., Allen A.J., Hamon M., Purper-Ouakil D., Gorwood P. A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). Neuropsychopharmacology 2009, 34:2135-2142.
41. Retz W., Rosler M., Kissling C., Wiemann S., Hunnerkopf R., Coogan A., Thome J., Freitag C. Norepinephrine transporter and catecholamine-O-methyltransferase gene variants and attention-deficit/hyperactivity disorder symptoms in adults. Journal of Neural Transmission 2008, 115:323-329.
42. Ryu S.H., Lee S.H., Lee H.J., Cha J.H., Ham B.J., Han C.S., Choi M.J., Lee M.S. Association between norepinephrine transporter gene polymorphism and major depression. Neuropsychobiology 2004, 49:174-177.
43. Shin, J.Y., Yang, J.W., Jang, W.S., Hong, S.D., 2007. Prescription status and efficacy of OROS-MPH and parent perception in children with attention deficit hyperactivity disorder: multicenter observational study during 4weeks. Korean Journal of psychopharmacology 18, 50-59.
44. Solanto M.V. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behavioural Brain Research 1998, 94:127-152.
45. Spencer T., Biederman J., Wilens T., Harding M., O'Donnell D., Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. Journal of the American Academy of Child and Adolescent Psychiatry 1996, 35:409-432.
46. Steele M., Weiss M., Swanson J., Wang J., Prinzo R.S., Binder C.E. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder. Canadian Journal of Clinical Pharmacology 2006, 13:e50-e62.
47. Stein M.A., Sarampote C.S., Waldman I.D., Robb A.S., Conlon C., Pearl P.L., Black D.O., Seymour K.E., Newcorn J.H. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics 2003, 112:e404.
48. Swanson J., Gupta S., Lam A., Shoulson I., Lerner M., Modi N., Lindemulder E., Wigal S. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Archives of General Psychiatry 2003, 60:204-211.
49. Vaidya C.J., Austin G., Kirkorian G., Ridlehuber H.W., Desmond J.E., Glover G.H., Gabrieli J.D. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proceeding of the National Academy of Sciences of the United States of America 1998, 95:14494-14499.
50. Wilens T., Pelham W., Stein M., Conners C.K., Abikoff H., Atkins M., August G., Greenhill L., McBurnett K., Palumbo D., Swanson J., Wolraich M. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. Journal of the American Academy of Child and Adolescent Psychiatry 2003, 42:424-433.
51. Wolraich M.L., Greenhill L.L., Pelham W., Swanson J., Wilens T., Palumbo D., Atkins M., McBurnett K., Bukstein O., August G. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001, 108:883-892.
52. Xu X., Knight J., Brookes K., Mill J., Sham P., Craig I., Taylor E., Asherson P. DNA pooling analysis of 21 norepinephrine transporter gene SNPs with attention deficit hyperactivity disorder: no evidence for association. American Journal of Medical Genetics B Neuropsychiatry Genetics 2005, 134:115-118.
53. Yang L., Wang Y.F., Li J., Faraone S.V. Association of norepinephrine transporter gene with methylphenidate response. Journal of the American Academy of Child and Adolescent Psychiatry 2004, 43:1154-1158.
54. Zill P., Engel R., Baghai T.C., Juckel G., Frodl T., Muller-Siecheneder F., Zwanzger P., Schule C., Minov C., Behrens S., Rupprecht R., Hegerl U., Moller H.J., Bondy B. Identification of a naturally occurring polymorphism in the promoter region of the norepinephrine transporter and analysis in major depression. Neuropsychopharmacology 2002, 26:489-493.